Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 666-672

  Sterling, Timothy R ^a,b,e   Lyles, Cynthia M ^b   Vlahov, David ^a,b,d   Astemborski, Jacquie ^b   Margolick, Joseph B ^b   Quinn, Thomas C ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NEW YORK ACADEMY OF MEDICINE   (United States)

^e Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SEROCONVERSION; SEX DIFFERENCE; VIRUS PATHOGENESIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV ANTIBODIES; HIV SEROPOSITIVITY; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; REFERENCE VALUES; REGRESSION ANALYSIS; RNA, VIRAL; SEX CHARACTERISTICS; TIME FACTORS; VIRAL LOAD;

EID: 0032823438     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314967     Document Type: Article

References (37)

1. 1. Jurriaans S, van Gemen B, Weverling JG, et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994; 204:223-33.
2. 2. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-9.
3. 3. Farzadegan H, Henrard DR, Kleeberger CA, et al. Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:448-55.
4. 4. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995; 274:554-8.
5. 5. Craib KJ, Strathdee SA, Hogg RS, et al. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality. J Infect Dis 1997; 176:798-800.
6. 6. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
7. - lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
8. 8. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996; 276:105-10.
9. 9. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious diseuse death in HIV-infected injection drug users. JAMA 1998; 279:35-40.
10. 10. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society USA panel. JAMA 1998; 280:78-86.
11. 11. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1998; 128:1079-100.
12. 12. O'Brien TR, Rosenberg PS, Yellin K, Goedert JJ. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:155-61.
13. 13. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335:1091-8.
14. 14. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352:1510-4.
15. 15. Evans JS, Nims T, Cooley J, et al. Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. J Infect Dis 1997; 175:795-800.
16. 16. Bush CE, Donovan RM, Markowitz N, Baxa D, Kvale P, Saravolatz LD. Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia. J Clin Microbiol 1996; 34:970-2.
17. 17. Fang G, Siegal FP, Weiser B, et al. Measurement of human immunodeficiency virus (HIV) type 1 RNA load distinguishes progressive infection from nonprogressive HIV-1 infection in men and women. Clin Infect Dis 1997; 25:332-3.
18. 18. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study: a longitudinal study of HIV infection in intravenous drug users: description of methods. J Drug Issues 1991;21:759-76.
19. 19. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17):1-19.
20. 20. Hoffman RA, Kunge PC, Hansen WP, Goldstein G. Simple and rapid measurement of human T-lymphocytes and their subclasses in peripheral blood. Proc Natl Acad Sci USA 1980; 77:4914-7.
21. 21. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort experience. Clin Immunol Immunopathol 1990; 55:173-86.
22. 22. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillem PME, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495-503.
23. 23. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary, NC: SAS Institute, 1996.
24. 24. Beatty ME, Broisman L. Comparison of the rates of CD4 count decline among HIV-infected women and men. AIDS 1995; 9:529-30.
25. 25. Love A, Sigurdsson JR, Stanzeit B, Briem H, Rikardsdottir H, Widell A. Characteristics of hepatitis C virus among intravenous drug users in Iceland. Am J Epidemiol 1996; 143:631-6.
26. 26. Thomas DL, Rai R, Anania F, et al. A prospective investigation of hepatitis C viral load. Hepatology 1998; 28:568A.
27. 27. Tilzey AJ, Palmer SJ, Barrow S, et al. Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. BMJ 1992; 304:1272-6.
28. 28. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989:87(Suppl 3A):36S-40S.
29. 29. Green MS, Shohat T, Lerman Y, et al. Sex differences in the humoral antibody response to live measles vaccine in young adults. Int J Epidemiol 1994; 23:1078-81.
30. 30. Leon ME, Ward B, Kanashiro R, et al. Immunologic parameters 2 years after high-titer measles immunization in Peruvian children. J Infect Dis 1993; 168:1097-104.
31. 31. Mitchell LA, Zhang T, Tingle AJ. Differential antibody responses to rubella virus infection in males and females. J Infect Dis 1992; 166:1258-65.
32. 32. Shanker G, Sorci-Thomas M, Adams MR. Estrogen modulates the expression of tumor necrosis factor alpha mRNA in phorbol ester-stimulated human monocytic THP-1 cells. Lymphokine Cytokine Res 1994; 13:377-82.
33. 33. Mellors JW, Griffith BP, Ortiz MA, Landry ML, Ryan JL. Tumor necrosis factor-α/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages. J Infect Dis 1991; 163:78-82.
34. 34. Grossman C. Possible underlying mechanisms of sexual dimorphism in the immune response, fact and hypothesis. J Steroid Biochem 1989; 34:241-51.
35. 35. Musey L, Hughes J, Schaker T, Shea T, Corey L, McElrath MJ. Cytotoxic T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267-74.
36. 36. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
37. 37. Pezzotti P, Phillips AN, Dorrucci M, et al. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. BMJ 1996; 313:583-6.